Ciriana Orabona
Perugia, 06132, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 65 publications
Discovery of a Dual IDO1/TDO Inhibitor That Modulates Enzymatic Activity and IDO1/SHP-2 Signaling.
Journal: Journal of medicinal chemistry
Published: July 22, 2026
Adverse pro-tumorigenic effects of IDO1 catalytic inhibitors mediated by the non-enzymatic function of IDO1 in tumor cells.
Journal: Frontiers in immunology
Published: August 06, 2025
Ligand-induced conformations and dynamic allosteric motions of IDO1 affecting the recruitment of a protein signaling partner.
Journal: Communications chemistry
Published: January 30, 2025
Monovalent pseudo-natural products supercharge degradation of IDO1 by its native E3 KLHDC3.
Journal: Nature chemistry
Published: December 10, 2024
Epigenetic Modeling of Jumping Translocations of 1q Heterochromatin in Acute Myeloid Leukemia After 5'-Azacytidine Treatment.
Journal: Genes, chromosomes & cancer
Published: September 05, 2024
Epacadostat stabilizes the apo-form of IDO1 and signals a pro-tumorigenic pathway in human ovarian cancer cells.
Journal: Frontiers in immunology
Published: November 29, 2023
Membrane Localization and Phosphorylation of Indoleamine 2,3-Dioxygenase 2 (IDO2) in A549 Human Lung Adenocarcinoma Cells: First Steps in Exploring Its Signaling Function.
Journal: International journal of molecular sciences
Published: September 18, 2023
Editorial: Heme proteins: key players in the regulation of immune responses.
Journal: Frontiers in immunology
Published: July 19, 2023
The signaling function of IDO1 incites the malignant progression of mouse B16 melanoma.
Journal: Oncoimmunology
Published: February 03, 2023
The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1.
Journal: Frontiers in immunology
Published: December 30, 2022
Last Updated: 09/26/2026